Actuate Therapeutics’ (ACTU) “Buy” Rating Reiterated at HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 227.87% from the company’s current price.

Several other equities research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Thursday, November 13th. Wall Street Zen upgraded shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Finally, B. Riley initiated coverage on Actuate Therapeutics in a report on Tuesday, August 26th. They issued a “buy” rating and a $20.00 price target for the company. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.33.

Actuate Therapeutics Trading Up 3.0%

Shares of ACTU opened at $6.10 on Wednesday. Actuate Therapeutics has a twelve month low of $5.47 and a twelve month high of $11.99. The firm has a market capitalization of $141.78 million, a P/E ratio of -7.01 and a beta of -0.23. The stock’s fifty day simple moving average is $6.88 and its 200 day simple moving average is $7.69.

Actuate Therapeutics (NASDAQ:ACTU) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02.

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC acquired a new position in Actuate Therapeutics in the 1st quarter worth $70,000. Sfmg LLC purchased a new stake in shares of Actuate Therapeutics during the first quarter worth about $74,000. Bank of America Corp DE lifted its stake in shares of Actuate Therapeutics by 61,068.0% in the second quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after acquiring an additional 15,267 shares in the last quarter. New York State Common Retirement Fund purchased a new position in Actuate Therapeutics in the second quarter valued at about $105,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Actuate Therapeutics by 492.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after purchasing an additional 15,393 shares in the last quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.